TABLE 1.

Key Questions to Be Addressed by MAT-LINK

Clinical management of OUD in pregnancy   • What characteristics of pregnant women with OUD (e.g., patterns of opioid use) predict which regimen is likely to be most effective before, during, and after pregnancy?   • How often and why do pregnant women switch OUD treatment regimens?

OUD treatment regimen and pregnancy and infant outcomes  Do the following outcomes differ across OUD treatment regimens?   • Risk of relapse and/or overdose among pregnant and postpartum women   • Pain management during labor and delivery   • Frequency of adverse birth outcomes (e.g., preterm birth, pregnancy loss, and growth restriction)   • Risk of NAS and other infant outcomes   • Risk of developmental delay and other childhood outcomes

Other risk factors related to OUD treatment  Does the risk of pregnancy, infant, or child health outcomes differ depending on the presence of the following other factors?   • History of maternal physical or mental conditions   • Medications during pregnancy   • Specific polysubstance combinations used during pregnancy   • Development of NAS or NAS severity in infants   • Management of NAS with nonpharmacologic and/or pharmacologic regimens   • Receipt of postdischarge services and plans of safe care

MAT-LINK, MATernaL and Infant Network to Understand Outcomes Associated with Treatment for Opioid Use Disorder during Pregnancy; NAS, neonatal abstinence syndrome; OUD, opioid use disorder.